Oxytocin for Postpartum Hemorrhage
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drug oxytocin for postpartum hemorrhage?
Is oxytocin safe for use in humans?
Oxytocin, including its synthetic form Syntocinon, has been used safely in thousands of patients without observed side effects like vasospasm (narrowing of blood vessels) or anaphylactic reaction (severe allergic reaction). It is generally considered safe when used with proper supervision and dosage adjustment.23678
How is the drug oxytocin unique in treating postpartum hemorrhage?
What is the purpose of this trial?
This study is designed to determine the minimal effective oxytocin maintenance infusion required in labouring women undergoing cesarean delivery to achieve the best effect. Oxytocin is a drug that is routinely used to help the uterus to contract and keep it contracted after delivery. Consequently, it will help to reduce blood loss after delivery. In order to determine the minimal effective dose, the investigators will conduct a dose-finding study. The first patient will receive a set oxytocin infusion. The next patient's infusion dose of oxytocin, will either increase or decrease, depending on how the previous patient responds in terms of uterine tone. If the response is satisfactory with the infusion dose used, the next patient will either receive the same infusion dose or it will be decreased depending on a probability of 1:9. If the response is not satisfactory, then the infusion dose will increase for the next patient. The dose for each patient will be determined based on the results of the uterine contraction of the previous patient.The investigators hypothesize that the ED90 of the oxytocin infusion rate to maintain adequate uterine tone in labouring women with induced or augmented labour undergoing cesarean delivery, following an initial effective bolus dose, would be lower than 0.74 IU/min (44 IU/h), which was found as the ED90 in a previous study, without an initial bolus dose prior to the infusion.
Research Team
Mrinalini Balki, MD
Principal Investigator
MOUNT SINAI HOSPITAL
Eligibility Criteria
This trial is for women in labor who are having a cesarean delivery under neuraxial anesthesia and have been exposed to oxytocin for at least 3 hours. It's not suitable for those with hypertension, severe heart issues, allergies to oxytocin, contraindications to neuraxial anesthesia, or if general anesthesia becomes necessary during surgery.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive varying doses of oxytocin infusion to determine the minimal effective dose for maintaining uterine tone during cesarean delivery
Postoperative Monitoring
Participants are monitored for uterine tone and other physiological responses in the post anesthetic care unit (PACU)
Follow-up
Participants are monitored for safety and effectiveness after treatment, including blood loss and need for additional uterotonic medication
Treatment Details
Interventions
- Oxytocin
Oxytocin is already approved in United States, European Union, Canada for the following indications:
- Induction of labor
- Augmentation of labor
- Control of postpartum bleeding
- Induction of labor
- Augmentation of labor
- Control of postpartum bleeding
- Induction of labor
- Augmentation of labor
- Control of postpartum bleeding
Find a Clinic Near You
Who Is Running the Clinical Trial?
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Lead Sponsor